Drug intelligence / Profile preview

MTI-301-C

Development stage: Unknown
Lead developer: Modulation Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

MTI-301-C is an orally bioavailable small molecule inhibitor of stearoyl-CoA desaturase 1 (SCD-1) being developed by Modulation Therapeutics. SCD-1 is a rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids, and its overexpression is associated with tumor cell survival, proliferation, and metabolic reprogramming. MTI-301-C is specifically designed to exploit the SCD-1 dependence of certain cancers, including triple-negative breast cancer (TNBC) and hepatocellular carcinoma (HCC). The program is currently in Phase 1 clinical development for advanced solid tumor malignancies, aiming to disrupt cancer cell metabolism and membrane integrity.

Targets

SCD1 (Stearoyl-CoA desaturase 1)

Beyond the preview

Go deeper on MTI-301-C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTI-301-C.

Explore the full profile